Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 3/20 | 0.40 |
| ▸ | ATP4B | P51164 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816326 | 1.00 | ATP4A (0.40) | ATP4AATP4BCYP3A4CYP2C9BRD4 | |
| SCHEMBL4590723 | 0.83 | ATP4A (0.35) | ATP4AATP4BCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL4591093 | 0.83 | ATP4A (0.33) | ATP4AATP4B | |
| SCHEMBL4590855 | 0.83 | ATP4A (0.33) | ATP4AATP4B | |
| SCHEMBL4590828 | 0.83 | ATP4A (0.35) | ATP4AATP4BCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL4591100 | 0.82 | ATP4A (0.34) | ATP4AATP4BCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL4591074 | 0.82 | ATP4A (0.34) | ATP4AATP4BCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL6023510 | 0.81 | ATP4A (0.34) | ATP4AATP4BCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL4590864 | 0.80 | ATP4A (0.33) | ATP4AATP4B | |
| SCHEMBL4591567 | 0.80 | ATP4A (0.33) | ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879891-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-23 | — | — | EP | claimed |
| EP-1877410-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-16 | — | — | EP | claimed |
| WO-2006117315-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECCTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | claimed |
| WO-2006117316-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE US ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | claimed |
| EP-1879891-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877410-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1286999-B1 | PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | NYCOMED GMBH (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-7189736-B2 | Prodrugs of imidazopyridine derivatives | ALTANA PHARMA AG (DE) | 2007-03-13 | — | — | US | disclosed |
| WO-2006117315-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECCTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117316-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE US ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | disclosed |
| EP-1313739-B1 | ALKYLATED IMIDAZOPYRIDINE DERIVATIVES | ALTANA PHARMA AG (DE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1313740-B1 | PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES | ALTANA PHARMA AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2001072754-A9 | ALKYLATED IMIDAZOPYRIDINE DERIVATIVES | ALTANA PHARMA AG (DE) | 2004-05-06 | — | — | WO | disclosed |
| US-20030158193-A1 | Alkylated imidazopyridine derivatives | ALTANA PHARMA AG (DE) | 2003-08-21 | — | — | US | disclosed |
| US-20030125327-A1 | Prodrugs of imidazopyridine derivatives | ALTANA PHARMA AG (DE) | 2003-07-03 | — | — | US | disclosed |
| US-20030100578-A1 | Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2003-05-29 | — | — | US | disclosed |
| EP-1313740-A1 | PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES | ALTANA Pharma AG (DE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1286999-A1 | PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA Pharma AG (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001072755-A1 | PYRANO[2,3-C]IMIDAZO[-1,2-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072756-A1 | PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125327-A1 | Prodrugs of imidazopyridine derivatives | SI, CYP2E1, UGT1A1 | ATP4A 518/4885ATP4B 1271/4885CYP3A4 10/4885 |
| US-20030100578-A1 | Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders | ALPI, GIPR, SLC10A2 | ATP4A 618/4885ATP4B 1962/4885CYP3A4 67/4885 |
| US-20030158193-A1 | Alkylated imidazopyridine derivatives | CYP2E1, SLC10A2, FABP2 | ATP4A 276/4885ATP4B 1054/4885CYP3A4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.